Silent diffuse low-grade glioma: Toward screening and preventive treatment?

Cancer

Volumn 120, Issue 12, 2014, Pages 1758-1762

  Mandonnet, Emmanuel ^a,b,c   De Witt Hamer, Philip ^d   Pallud, Johan ^b,e   Bauchet, Luc ^f   Whittle, Ian ^g   Duffau, Hugues ^f,h  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Imaging and Modeling Laboratory for Neurobiology and Oncology Medical Research Unit 8165   (France)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CENTRE HOSPITALIER SAINTE ANNE   (France)

^f GUI DE CHAULIAC HOSPITAL   (France)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h Montpellier University Medical Center   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CLINICALLY SILENT STAGE; COST EFFECTIVENESS ANALYSIS; DIFFUSE GLIOMA GLIOMA; GLIOMA; HEALTH CARE POLICY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT STAGE; PRIORITY JOURNAL; REVIEW; SYMPTOMATIC STAGE;

BRAIN NEOPLASMS; GLIOMA; HUMANS; MASS SCREENING; MODELS, BIOLOGICAL;

EID: 84902163692     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28610     Document Type: Review

References (34)

1. Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years. Neuro Oncol. 2013; 15: 1102-1110.
2. Whittle IR,. What is the place of conservative management for adult supratentorial low-grade glioma? Adv Tech Stand Neurosurg. 2010; 35: 65-79.
3. Soffietti R, Baumert BG, Bello L, et al. European Federation of Neurological Societies. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010; 17: 1124-1133.
4. Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization grade II gliomas: a series of 1097 cases. J Neurosurg. 2013; 118: 1157-1168.
5. Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012; 308: 1881-1888.
6. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008; 26: 1338-1345.
7. Duffau H,. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta Neurochir (Wien) 154: 575-584, 2011; discussion 584.
8. Duffau H,. The rationale to perform early resection in incidental diffuse low-grade glioma: toward a "preventive surgical neuro-oncology" [serial online]. World Neurosurg. 2013; 80: e115-e117.
9. Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Ann Neurol. 2010; 68: 727-733.
10. Potts MB, Smith JS, Molinaro AM, Berger MS,. Natural history and surgical management of incidentally discovered low-grade gliomas. J Neurosurg. 2012; 116: 365-372.
11. Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance imaging: systematic review and optimal treatment paradigm [serial online]. Neurosurg Focus. 2011; 31: E12.
12. Shah AH, Madhavan K, Sastry A, Komotar RJ,. Managing intracranial incidental findings suggestive of low-grade glioma: learning from experience [serial online]. World Neurosurg. 2013; 80: e75-e77.
13. Yordanova YN, Moritz-Gasser S, Duffau H,. Awake surgery for WHO grade II gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection. Clinical article. J Neurosurg. 2011; 115: 232-239.
14. de Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS,. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 2012; 30: 2559-2565.
15. Kelly PJ,. Gliomas: survival, origin and early detection [serial online]. Surg Neurol Int. 2010; 1: 96.
16. Floeth FW, Sabel M, Stoffels G, et al. Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions. J Nucl Med. 2008; 49: 730-737.
17. National Institute of Statistics and Economic Studies (INSEE). INSEE database, 2012. Available at: http://www.insee.fr/fr/bases-de-donnees/bsweb/ serie.asp?idbank=000436394. Accessed on September 1, 2013.
18. Morris Z, Whiteley WN, Longstreth WT Jr, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis [serial online]. BMJ. 2009; 339: b3016.
19. Zouaoui S, Rigau V, Mathieu-Daude H, et al. [French brain tumor database: general results on 40,000 cases, main current applications and future prospects]. Neurochirurgie. 2012; 58: 4-13.
20. Yan W, Zhang W, You G, et al. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China [serial online]. PLoS One. 2012; 7: e30339.
21. Zhang CB, Bao ZS, Wang HJ, et al. Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China. J Cancer Res Clin Oncol. 2014; 140: 45-51.
22. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27: 4150-4154.
23. Cooney LM Jr, Solitare GB,. Primary intracranial tumors in the elderly. Geriatrics. 1972; 27: 94-104.
24. DiMaio SM, DiMaio VJ, Kirkpatrick JB,. Sudden, unexpected deaths due to primary intracranial neoplasms. Am J Forensic Med Pathol. 1980; 1: 29-45.
25. Eberhart CG, Morrison A, Gyure KA, Frazier J, Smialek JE, Troncoso JC,. Decreasing incidence of sudden death due to undiagnosed primary central nervous system tumors. Arch Pathol Lab Med. 2001; 125: 1024-1030.
26. Gezelius C, Eriksson A,. Neoplastic disease in a medicolegal autopsy material. A retrospective study in northern Sweden. Z Rechtsmed. 1988; 101: 115-130.
27. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003; 53: 524-528.
28. Pallud J, Mandonnet E, Duffau H, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol. 2006; 60: 380-383.
29. Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade glioma: a plea for systematic measurement of growth rates. Neurosurgery. 2012; 71: 729-740.
30. Pallud J, Capelle L, Taillandier L, Duffau H, Mandonnet E,. The silent phase of diffuse low-grade gliomas. Is it when we missed the action? Acta Neurochir (Wien). 2013; 155: 2237-2242.
31. Pallud J, Varlet P, Devaux B, et al. Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities. Neurology. 2010; 74: 1724-1731.
32. Gerin C, Pallud J, Grammaticos B, et al. Improving the time-machine: estimating date of birth of grade II gliomas. Cell Prolif. 2011; 45: 76-90.
33. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012; 380: 1778-1786.
34. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.